By Andrew Nusca / Fortune
January 27, 2016

The laboratory practices of Theranos, the embattled blood-testing startup led by entrepreneur Elizabeth Holmes, “pose immediate jeopardy to patient safety,” according to a letter from the U.S. Department of Health and Human Services on Monday.

The Theranos lab was surveyed by the Centers for Medicare and Medicaid Services for compliance with the Clinical Laboratory Improvement Amendments of 1988 on Nov. 20, 2015.

The lab was found deficient for hematology (the study of blood), analytic systems, and other practices.

Developing story…

This article originally appeared on Fortune.com

Contact us at editors@time.com.

SPONSORED FINANCIAL CONTENT

Read More From TIME

EDIT POST